Aclaris Therapeutics Inc (NAS:ACRS)
$ 2.22 0.05 (2.3%) Market Cap: 158.39 Mil Enterprise Value: 36.85 Mil PE Ratio: 0 PB Ratio: 1.18 GF Score: 58/100

Aclaris Therapeutics, Inc. - Special Call Transcript

Jan 19, 2021 / 01:00PM GMT
Release Date Price: $18.83 (+220.24%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Aclaris Therapeutics presents positive preliminary top line data for ATI-450-RA-201. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I'd now like to hand the conference over to your speaker today, Kamil Ali-Jackson, Chief Legal Officer. Thank you. Please go ahead, ma'am.

Kamil Ali;Jackson
Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary

Thank you, Shannon. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing positive preliminary top line results from its Phase IIa clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, its investigational oral MK2 inhibitor, in subjects with moderate severe rheumatoid arthritis. For those of you who have not yet seen it, you will find the release posted under the Press Releases page of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot